Figure 2. Risk of Any Cancer With Topical Calcineurin Inhibitor (TCI) Treatment and Nonactive Comparator in Cohort Studies.
Relative risks (RRs) were calculated using random-effects inverse variance method. Marker size indicates weight; diamond size indicates heterogeneity. PIM indicates pimecrolimus; TAC, tacrolimus.